Eli Lilly in advanced talks to buy US cancer biotech for up to $2.5bn
8 hours ago · Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5bn, according to people close to the ...
Lilly in advanced talks to buy cancer biotech Scorpion for up to …
1 day ago · Eli Lilly is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks told Financial Times’ Oliver Barnes, Maria Heeter and ...
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay ...
8 hours ago · Eli Lilly (NYSE:LLY) is expected to pay around $1 billion upfront for the privately owned Scorpion, according to a Financial Times report on Friday, which cited people familiar with the matter ...
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says ... - MSN
Shares of Relay Therapeutics , which makes similar technology to Scorpion for fighting cancer, jumped 22% on Lilly news, though has now dropped 10%. More on Eli Lilly Novo Nordisk Vs.
Eli Lilly in advanced talks to buy US cancer biotech for up to $2.5bn
Scorpion’s founders include cancer expert Keith Flaherty, the director of clinical research at Massachusetts General Hospital Cancer Center. Flaherty was a co-founder of Loxo Oncology, which was bought by Eli Lilly for $8bn in 2019. Loxo Oncology became the centrepiece of Eli Lilly’s oncology strategy, however, the pharma group has also ...
Lilly Close to Acquire Cancer Biotech Scorpion Therapeutics for …
18 hours ago · -- Eli Lilly is nearing a deal to acquire privately held Scorpion Therapeutics, valuing the Boston-based company working on potential cancer treatments at around $2.5 billion, according to the...
Eli Lilly said to be in talks to buy Scorpion ... - Breaking The News
Eli Lilly and Company is in advanced talks to acquire biotechnology company Scorpion Therapeutics for $2.5 billion, the Financial Times reported on Friday, citing people briefed on the negotiations. A...
SABCS 2024 – Lilly's PI3Kα push is no longer mutation-specific
Dec 13, 2024 · Both molecules impressed clinically in PIK3CA-mutated breast cancer earlier this year, Scorpion's as monotherapy and Relay's in combination with Faslodex. Relay presented an update at SABCS, now reporting a 39% confirmed ORR among 31 patients, up from the 30% in 30 patients it press released in September.
Scorpion secures $150m to progress oncology pipeline
Jul 17, 2024 · Scorpion aims to continue progressing its clinical-stage EGFR inhibitor franchise, which includes STX-721 and STX-241, as well as its discovery pipeline of next-generation precision oncology assets.
OnKure hitches Reneo's ride to Nasdaq, with $65M PIPE to boot
May 13, 2024 · OnKure Therapeutics has merged with Reneo Pharmaceuticals, jumping onto Wall Street with $120 million and a lead breast cancer treatment challenging the likes of Eli Lilly, Relay and Scorpion....
- Some results have been removed